BeOne Medicines secures exemption from Section 232 pharmaceutical tariffs under U.S. onshoring deal

• BeOne Medicines reached a voluntary onshoring agreement with the U.S. government tied to expanded access for oncology medicines.
• The deal secures an exemption from Section 232 pharmaceutical tariffs, citing the company’s ongoing U.S. manufacturing investment.
• BeOne recently disclosed a USD 300 million onshoring expansion in Hopewell, New Jersey, lifting total U.S. manufacturing investment above USD 1 billion.
• The company also committed to price future FDA-approved products in line with other key developed markets under the GENEROUS Medicaid model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260831047788) on August 31, 2026, and is solely responsible for the information contained therein.